ARCL Organics (543993)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trading at ₹73.32 versus book value ₹75.52, a modest P/B discount of 0.97.
• ROCE of 20.33% shows decent operating capital productivity during good periods.
• ROE of 10.74% is acceptable if the loss-making quarter is a temporary cyclical dip.
• Small market cap of ₹59 Cr leaves room for operational leverage in a recovery.

Concerns

• Latest quarter shows a net loss of ₹9 Cr on sales of ₹53 Cr.
• Sales growth is negative at -13.7% and profit growth has deteriorated by -634.08%.
• Piotroski F-score of 3/9 indicates weak overall financial health.
• Stock trades far below the 52-week range (₹150.00 - ₹434.60), signaling severe market punishment; no dividend to cushion shareholders.

AI Analysis

At ₹73.32, ARCL Organics trades at 0.97 times book value of ₹75.52. That looks like a Graham-style margin of safety on assets. But an asset is only as safe as the earnings it can produce. The latest quarter reports sales of ₹53 crore and a net loss of ₹9 crore. Sales are down 13.7%, and profit growth has collapsed by 634%. This is a commodity chemical company, and the numbers smell like a cyclical trough or a deteriorating balance sheet. The 20.33% ROCE suggests that when operations run properly, the business can generate decent returns, and 10.74% ROE is respectable. Yet the Piotroski F-score of 3 out of 9 is a red flag; it points to weakening financial health, poor efficiency, or rising stress. Mr. Market has marked the stock down from a 52-week high of ₹434.60 to ₹73.32, which is even below the stated 52-week low. The P/E of 18.33 is not meaningful when the latest quarter is loss-making. There is no dividend, so shareholders need capital appreciation, and that requires a real earnings recovery. I cannot trust the book value until I know the liabilities, debt, and working capital. In commodity chemicals, today's cheap P/B can become tomorrow's value trap. This is not a wide-moat stalwart; it is a cyclical situation with a possible asset cushion. I would keep it on a watchlist and demand evidence of margin recovery and stable cash flows before investing. If the balance sheet is clean and the cycle turns, the current price may prove rewarding; if debt is high, the apparent discount to book value is imaginary.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer